Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an update.
ImmuneOnco Biopharmaceuticals has announced the successful dosing of the first patient in the Phase Ib/II trial for IMM2510 with chemotherapy as a first-line treatment for non-small cell lung cancer. The trial aims to enroll more patients, with initial results expected by the second half of 2025. Previous studies have shown promising efficacy and tolerability of IMM2510 across multiple solid tumors, indicating potential significant advancements in cancer treatment, positioning the company as a leader in innovative oncology solutions.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a company in the biopharmaceutical industry, focused on developing innovative cancer therapies. Its primary product, IMM2510, is a bispecific molecule targeting VEGF and PD-L1, designed to inhibit angiogenesis and enhance immune responses against tumors. The company’s market focus is on treating a variety of advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, and soft-tissue sarcoma.
YTD Price Performance: -5.43%
Average Trading Volume: 13,331,921
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$1.99B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.
